UroGen Pharma Competitors

UroGen Pharma (NASDAQ:URGN) and ImmunoGen (NASDAQ:IMGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Institutional & Insider Ownership

71.6% of UroGen Pharma shares are owned by institutional investors. Comparatively, 73.0% of ImmunoGen shares are owned by institutional investors. 12.0% of UroGen Pharma shares are owned by company insiders. Comparatively, 3.8% of ImmunoGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares UroGen Pharma and ImmunoGen's revenue, earnings per share and valuation.

ImmunoGen has higher revenue and earnings than UroGen Pharma. ImmunoGen is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

UroGen Pharma has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, ImmunoGen has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.

Profitability

This table compares UroGen Pharma and ImmunoGen's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for UroGen Pharma and ImmunoGen, as provided by MarketBeat.com.

UroGen Pharma presently has a consensus target price of $42.25, indicating a potential upside of 139.51%. ImmunoGen has a consensus target price of $10.10, indicating a potential upside of 32.72%. Given UroGen Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe UroGen Pharma is more favorable than ImmunoGen.

Summary

ImmunoGen beats UroGen Pharma on 8 of the 14 factors compared between the two stocks.

UroGen Pharma (NASDAQ:URGN) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Volatility & Risk

UroGen Pharma has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares UroGen Pharma and Cassava Sciences' net margins, return on equity and return on assets.

Insider and Institutional Ownership

71.6% of UroGen Pharma shares are owned by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are owned by institutional investors. 12.0% of UroGen Pharma shares are owned by company insiders. Comparatively, 13.7% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares UroGen Pharma and Cassava Sciences' revenue, earnings per share (EPS) and valuation.

Cassava Sciences has lower revenue, but higher earnings than UroGen Pharma. Cassava Sciences is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for UroGen Pharma and Cassava Sciences, as reported by MarketBeat.

UroGen Pharma presently has a consensus price target of $42.25, suggesting a potential upside of 139.51%. Cassava Sciences has a consensus price target of $35.3333, suggesting a potential downside of 0.86%. Given UroGen Pharma's higher probable upside, equities analysts plainly believe UroGen Pharma is more favorable than Cassava Sciences.

Summary

Cassava Sciences beats UroGen Pharma on 7 of the 11 factors compared between the two stocks.

Applied Molecular Transport (NASDAQ:AMTI) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Institutional & Insider Ownership

52.0% of Applied Molecular Transport shares are held by institutional investors. Comparatively, 71.6% of UroGen Pharma shares are held by institutional investors. 12.0% of UroGen Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for Applied Molecular Transport and UroGen Pharma, as provided by MarketBeat.com.

Applied Molecular Transport presently has a consensus target price of $68.75, indicating a potential upside of 64.91%. UroGen Pharma has a consensus target price of $42.25, indicating a potential upside of 139.51%. Given UroGen Pharma's higher probable upside, analysts clearly believe UroGen Pharma is more favorable than Applied Molecular Transport.

Earnings & Valuation

This table compares Applied Molecular Transport and UroGen Pharma's gross revenue, earnings per share (EPS) and valuation.

Applied Molecular Transport has higher earnings, but lower revenue than UroGen Pharma.

Profitability

This table compares Applied Molecular Transport and UroGen Pharma's net margins, return on equity and return on assets.

UroGen Pharma (NASDAQ:URGN) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for UroGen Pharma and Generation Bio, as provided by MarketBeat.

UroGen Pharma currently has a consensus target price of $42.25, suggesting a potential upside of 139.51%. Generation Bio has a consensus target price of $40.60, suggesting a potential upside of 52.80%. Given UroGen Pharma's higher possible upside, equities analysts plainly believe UroGen Pharma is more favorable than Generation Bio.

Insider & Institutional Ownership

71.6% of UroGen Pharma shares are held by institutional investors. Comparatively, 63.3% of Generation Bio shares are held by institutional investors. 12.0% of UroGen Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares UroGen Pharma and Generation Bio's top-line revenue, earnings per share (EPS) and valuation.

Generation Bio has lower revenue, but higher earnings than UroGen Pharma.

Profitability

This table compares UroGen Pharma and Generation Bio's net margins, return on equity and return on assets.

Summary

UroGen Pharma beats Generation Bio on 4 of the 7 factors compared between the two stocks.

Zealand Pharma A/S (NASDAQ:ZEAL) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Insider and Institutional Ownership

4.3% of Zealand Pharma A/S shares are owned by institutional investors. Comparatively, 71.6% of UroGen Pharma shares are owned by institutional investors. 12.0% of UroGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Zealand Pharma A/S and UroGen Pharma's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Zealand Pharma A/S and UroGen Pharma's gross revenue, earnings per share (EPS) and valuation.

Zealand Pharma A/S has higher revenue and earnings than UroGen Pharma. Zealand Pharma A/S is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Zealand Pharma A/S has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Zealand Pharma A/S and UroGen Pharma, as provided by MarketBeat.com.

Zealand Pharma A/S currently has a consensus price target of $43.00, indicating a potential upside of 35.39%. UroGen Pharma has a consensus price target of $42.25, indicating a potential upside of 139.51%. Given UroGen Pharma's higher possible upside, analysts clearly believe UroGen Pharma is more favorable than Zealand Pharma A/S.

Summary

UroGen Pharma beats Zealand Pharma A/S on 8 of the 13 factors compared between the two stocks.

UroGen Pharma (NASDAQ:URGN) and Antibe Therapeutics (NASDAQ:ATBPD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Earnings & Valuation

This table compares UroGen Pharma and Antibe Therapeutics' gross revenue, earnings per share and valuation.

Antibe Therapeutics has higher revenue and earnings than UroGen Pharma. Antibe Therapeutics is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

UroGen Pharma has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Antibe Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Institutional & Insider Ownership

71.6% of UroGen Pharma shares are held by institutional investors. 12.0% of UroGen Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares UroGen Pharma and Antibe Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for UroGen Pharma and Antibe Therapeutics, as reported by MarketBeat.

UroGen Pharma currently has a consensus price target of $42.25, suggesting a potential upside of 139.51%. Given UroGen Pharma's higher possible upside, research analysts plainly believe UroGen Pharma is more favorable than Antibe Therapeutics.

Summary

UroGen Pharma beats Antibe Therapeutics on 10 of the 13 factors compared between the two stocks.